9.42
0.00
(0.00%)
At close: January 10 at 3:00:00 PM EST
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Thomas Meier Ph.D. | Founder & Chairman | 109.65k | -- | 1962 |
| Mr. Dario Eklund | Chief Executive Officer | 1.1M | -- | 1968 |
| Mr. Andrew P. Smith CGMA, FCMA | Chief Financial Officer | -- | -- | 1962 |
| Mr. Oliver Strub | Head of Compliance | -- | -- | 1963 |
| Mr. Shabir Hasham M.D. | Chief Medical Officer | -- | -- | -- |
| Mr. Marc Schrader | Chief Technology Officer | -- | -- | -- |
| Dr. Oliver P. Kronenberg | Chief Legal Officer & Corporate Secretary | -- | -- | -- |
| Mr. Neville Kodkani M.D. | Head of Global Marketing & Partner Management | -- | -- | -- |
| Ms. Sarah Holmes-Klotz | Head of People & Culture | -- | -- | -- |
| Mr. Andreas Missy | Executive Vice President of Corporate Planning & Business Development | -- | -- | -- |
Santhera Pharmaceuticals Holding AG
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 44
Description
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
Corporate Governance
Santhera Pharmaceuticals Holding AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
2HA.MU Spero Therapeutics Inc
0.9680
-2.52%
FYB.F Formycon AG
62.50
+1.63%
ARTH Arch Therapeutics, Inc.
0.1701
-14.95%
FYB.DE Formycon AG
62.70
+1.46%
207940.KS Samsung Biologics Co.,Ltd.
1,000,000.00
-0.60%
RKV.V Rakovina Therapeutics Inc.
0.1750
-2.78%
ACOG Alpha Cognition Inc.
6.10
+6.56%
22UA.DE BioNTech SE
119.40
+0.93%
ENTA Enanta Pharmaceuticals, Inc.
5.09
-1.36%
TVTX Travere Therapeutics, Inc.
18.09
-4.79%